Totals
- Total revenue
- $3,093,277
- Total expenses
- $2,940,619
- Contributions and grants received
- $2,178,724
- Grants paid
- $702,747
- Program service revenue
- $586,491
- Investment income
- $120,430
- Other revenue
- $207,632
- Total assets, end of year
- $4,610,157
- Total liabilities, end of year
- $839,132
- Net assets or fund balances, end of year
- $3,771,025
- Program services expenses (Part IX)
- $2,336,431
- Management and general expenses
- $244,434
- Fundraising expenses
- $359,754
- Program service expenses (Part III)
- $2,336,431
Program services were 79.5% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1e , Government grants (contributions)
$299,819
-
1f , All other contributions, gifts and grants
$1,878,905
-
2a , Program service revenue: CORPORATE SUPPORT
total $343,483 · related or exempt $343,483
-
2b , Program service revenue: PHARMA CONSORTIUM
total $105,000 · related or exempt $105,000
-
2c , Program service revenue: CLINICAL TRIALS FEES
total $68,358 · related or exempt $68,358
-
2d , Program service revenue: OTHER PROGRAM REVENUE
total $41,352 · related or exempt $41,352
-
2e , Program service revenue: GREAT PROGRAM
total $28,298 · related or exempt $28,298
-
3 , Investment income
total $120,430 · excluded $120,430
-
8a , Fundraising events: gross income
$364,973
-
8b , Fundraising events: direct expenses
$157,341
-
8c , Net income from fundraising events
total $207,632 · excluded $207,632
Functional expenses
Part IX, the statement of functional expenses.
-
1 , Grants to domestic organizations and governments
total $100,000 · program services $100,000
-
3 , Grants to foreign organizations and individuals
total $602,747 · program services $602,747
-
5 , Compensation of officers, directors and key employees
total $470,750 · program services $341,868 · management and general $29,709 · fundraising $99,173
-
7 , Other salaries and wages
total $1,071,523 · program services $935,555 · management and general $14,820 · fundraising $121,148
-
9 , Other employee benefits
total $38,735 · program services $30,602 · management and general $2,891 · fundraising $5,242
-
10 , Payroll taxes
total $97,011 · program services $80,025 · management and general $1,562 · fundraising $15,424
-
11b , Fees: legal
total $85,842 · management and general $85,842
-
11c , Fees: accounting
total $19,800 · program services $16,179 · management and general $920 · fundraising $2,701
-
11f , Fees: investment management
total $29,455 · management and general $29,455
-
11g , Fees: other
total $98,717 · program services $63,483 · management and general $34,974 · fundraising $260
-
12 , Advertising and promotion
total $6,835 · program services $5,016 · management and general $21 · fundraising $1,798
-
13 , Office expenses
total $57,276 · program services $37,714 · management and general $495 · fundraising $19,067
-
14 , Information technology
total $62,145 · program services $60,256 · management and general $1,086 · fundraising $803
-
16 , Occupancy
total $1,162 · management and general $1,162
-
17 , Travel
total $54,806 · program services $21,338 · management and general $3,983 · fundraising $29,485
-
19 , Conferences, conventions and meetings
total $5,599 · program services $4,040 · management and general $605 · fundraising $954
-
20 , Interest
total $14,702 · management and general $14,702
-
22 , Depreciation, depletion and amortization
total $17,754 · program services $17,200 · fundraising $554
-
23 , Insurance
total $5,926 · management and general $5,926
-
24a , Other expenses: DUES AND SUBSCRIPTIONS
total $33,255 · program services $5,369 · management and general $4,882 · fundraising $23,004
-
24b , Other expenses: BANK CHARGES & OTHER FEES
total $19,965 · program services $270 · management and general $150 · fundraising $19,545
-
24c , Other expenses: MISCELLANEOUS
total $18,951 · management and general $809 · fundraising $18,142
-
24d , Other expenses: OTHER GIFTS AND DONATIONS
total $9,207 · program services $6,590 · management and general $1,592 · fundraising $1,025
-
24e , All other expenses
total $18,456 · program services $8,179 · management and general $8,848 · fundraising $1,429
Balance sheet
Part X, book values.
-
1 , Cash, non-interest-bearing
beginning of year $527,295 · end of year $302,186
-
2 , Savings and temporary cash investments
end of year $130,098
-
3 , Pledges and grants receivable
beginning of year $522,248 · end of year $476,047
-
4 , Accounts receivable
beginning of year $195,522 · end of year $133,148
-
9 , Prepaid expenses and deferred charges
beginning of year $86,714 · end of year $69,255
-
10a , Land, buildings and equipment: cost or other basis
$17,731
-
10b , Land, buildings and equipment: accumulated depreciation
$17,085
-
10c , Land, buildings and equipment, net
beginning of year $1,201 · end of year $646
-
11 , Investments: publicly traded securities
beginning of year $3,312,726 · end of year $3,498,777
-
17 , Accounts payable and accrued expenses
beginning of year $100,221 · end of year $159,373
-
18 , Grants payable
beginning of year $201,200 · end of year $65,000
-
19 , Deferred revenue
beginning of year $851,975 · end of year $614,759
-
27 , Net assets without donor restrictions
beginning of year $1,523,672 · end of year $1,511,287
-
28 , Net assets with donor restrictions
beginning of year $1,968,638 · end of year $2,259,738
Mission and programs · 2022
Mission
THE NATIONAL FOUNDATION FOR CELIAC AWARENESS, DOING BUSINESS AS BEYOND CELIAC, UNITES WITH PATIENTS AND PARTNERS TO DRIVE DIAGNOSIS, ADVANCE RESEARCH AND ACCELERATE THE DISCOVERY OF NEW TREATMENTS AND A CURE.
Activities or mission (Part I)
MISSION STATEMENT: THE NATIONAL FOUNDATION FOR CELIAC AWARENESS, DOING BUSINESS AS BEYOND CELIAC, UNITES WITH PATIENTS AND PARTNERS TO DRIVE DIAGNOSIS, ADVANCE RESEARCH AND ACCELERATE THE DISCOVERY OF NEW TREATMENTS AND A CURE. VISION STATEMENT: A WORLD IN WHICH PEOPLE WITH CELIAC DISEASE CAN LIVE HEALTHY LIVES, FREE FROM SOCIAL STIGMA AND FEAR OF GLUTEN EXPOSURE - A WORLD BEYOND CELIAC. DIVERSITY, EQUITY AND INCLUSION (DEI) MISSION BEYOND CELIAC FOSTERS A SENSE OF BELONGING BY ELEVATING UNDERREPRESENTED VOICES AS WE WORK TOGETHER FOR A CURE. WE SEEK TO BE A COMMUNITY THAT WELCOMES DIVERSE PERSPECTIVES AND PROVIDES MEANINGFUL OPPORTUNITIES TO EMPOWER MARGINALIZED POPULATIONS. DIVERSITY, EQUITY AND INCLUSION (DEI) VISION BEYOND CELIAC BELIEVES IN A WORLD WHERE WE ALL CAN LIVE HEALTHY LIVES FREE FROM BIAS AND BARRIERS. ACROSS OUR WORK, WE MUST ENGAGE DIVERSE PERSPECTIVES AND PROMOTE EQUITY IN OUR COMMUNITY TO REALIZE OUR VISION OF A WORLD BEYOND CELIAC. BEYOND CELIAC OVERVIEW SINCE 2003,
-
RESEARCH IN THE FIELD OF CELIAC DISEASE AND RELATED DISORDERS BEYOND CELIAC OFFERS GRANTS TO MEMBERS OF THE RESEARCH AND MEDICAL COMMUNITIES WHO ARE ADVANCING CELIAC DISEASE RESEARCH.USING A PATIENT- CENTERED APPROACH AND WORKING WITH THE BEYOND CELIAC SCIENTIFIC ADVISORY BOARD, CELIAC DISEASE SCIENTISTS ARE MAKING DISCOVERIES ABOUT CELIAC DISEASE WITH HELP FROM BEYOND CELIAC GRANTS. BEYOND CELIAC AWARDS MAJOR CELIAC DISEASE RESEARCH GRANTS THAT WILL ACCELERATE RESEARCH IN CELIAC DISEASE, NON-CELIAC GLUTEN SENSITIVITY ("GLUTEN SENSITIVITY") AND ASSOCIATED DISORDERS TO ADVANCE TREATMENTS BEYOND THE GLUTEN-FREE DIET AND, ONE DAY, A CURE. RECENT MAJOR GRANT AWARDS: PAUL KLENERMAN, PHD, A PROFESSOR OF GASTROENTEROLOGY AT THE UNIVERSITY OF OXFORD, OXFORD, ENGLAND, RECEIVED THE BEYOND CELIAC ESTABLISHED INVESTIGATOR AWARD. HE IS STUDYING KILLER T-CELLS THAT CAUSE THE ACTUAL TISSUE DAMAGE IN CELIAC DISEASE.INVESTIGATORS HAVE COMPILED THE RESULTS OF THEIR RESEARCH IN A MANUSCRIPT THEY HAVE SUBMITTED TO A SCIENTIFIC JOURNAL FOR PUBLICATION. ARNOLD HAN, MD, PHD, OF COLUMBIA UNIVERSITY, WAS AWARDED THE BEYOND CELIAC/SOCIETY FOR THE STUDY OF CELIAC DISEASE EARLY CAREER RESEARCH AWARD. HE IS INVESTIGATING THE ROLE OF CD8 T-CELLS TO ESTABLISH ANTIGEN SPECIFICTY. THE STUDY WILL ALSO INVESTIGATE CELIAC DISEASE MECHANISMS THROUGH AN INVITRO MODEL, CALLED AN ORGANOID. THIS RESEARCH IS A JOINT VENTURE THAT AIMS TO CORRECT A SIGNIFICANT GAP IN THE GASTROINTESTINAL AND AUTOIMMUNE DISEASE RESEARCH PORTFOLIO. NIGEL HOGGARD, MD AND IAIN CROALL, PHD, OF THE UNIVERSITY OF SHEFFIELD, UK, RECEIVED A BEYOND CELIAC ESTABLISHED INVESTIGATOR AWARD TO RESEARCH NEUROPATHOLOGY OF CELIAC DISEASE AND GLUTEN-RELATED DISORDERS. INVESTIGATORS WERE CLOSE TO CONCLUDING THEIR WORK AT THE END OF 2023 AND WERE BEGINNING TO PREPARE MANUSCRIPTS FOR SUBMISSION TO SCIENTIFIC JOURNALS NEUROPSYCHOLOGICAL IMPAIRMENT IN PEOPLE WITH CELIAC DISEASE CAN BE AS OR MORE DEBILITATING THAN THEIR GASTROINTESTINAL SYMPTOMS, AND IT HAS BEEN OVERLOOKED. THEIR STUDY IS FOCUSING ON HOW EFFECTIVELY THE GLUTEN-FREE DIET TREATS THESE NEUROLOGICAL PROBLEMS AND WILL FURTHER INVESTIGATE LONG-TERM EFFECTS ON COGNITIVE FUNCTION, SEVERITY OF DEPRESSION AND ANXIETY SYMPTOMS AND OVERALL QUALITY OF LIFE. SHALEV ITZKOVITS, PHD, WEIZMAN INSTITUTE OF SCIENCE, REHOVET, ISRAEL IN COLLABORATION WITH THE SCHNEIDER CHILDRENS MEDICAL CENTER, PETAH TIKVA, ISRAEL, RECEIVED A RESEARCH ACCELERATOR AWARD TO STUDY SHED CELL TRANSCIPTOMICS FOR THE IDENTIFICATION OF CELIAC DISEASE DYNAMICS. MICHAEL FITZPATRICK, MRCP, DPHIL OF THE UNIVERSITY OF OXFORD, OXFORD, UK, RECEIVED A RESEARCH ACCELERATOR AWARD TO STUDY NOVEL BIOMARKERS OF MUCOSAL DAMAGE FOR NON- INVASIVE DIAGNOSIS AND MONITORING OF CELIAC DISEASE. ROK SEON CHOUNG, MD, PHD, MAYO CLINIC, ROCHESTER, MINN, IN COLLABORATION WITH THE NAVAL MEDICAL CENTER, MARYLAND, AND ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, RECEIVED AN ESTABLISHED INVESTIGATOR AWARD TO STUDY IDENTIFYING PREDICTORS FOR PROGRESSIVE PHENOTYPES OF CELIAC DISEASE. SONIA GONCALVES PEREIRA, PHD, INSTITUTE POLITECNICO DE LINVESTIGATE, ASORTUGAL, IN COLLABORATION WITH THE CELIAC DISEASE RESEARCH CENTER AT TAMPERE UNIVERSITY, TAMPERE, FINLAND, RECEIVED AN ESTABLISHED INVESTIGATOR AWARD TO INVESTIGATE, AS PART OF THE CELIAC(TIV) STUDY, THE MECHANISMS OF GLUTEN-MICROBIOTA INTERACTION IN CELIAC DISEASE. KATI JUTTI- UUSITALO, PHD, TAMPERE UNIVERSITY, TAMPERE, FINLAND, RECEIVED AN ESTABLISHED INVESTIGATOR AWARED TO STUDY PRECLINIC TWO-D CELIAC DISEASE PATIENT-BASED IPSC-SMALL INTESTINAL EPITHELIAL IN VITRO MODEL RESEARCH PARTNERSHIPS: BEYOND CELIAC AND TAKEDA PHARMACEUTICAL COMPANY HAVE PARTNERED ON A DIVERSITY AND HEALTHCARE EQUITY INITIATIVE IN CELIAC DISEASE. BEYOND CELIAC AND TAKEDA PHARMACEUTICAL COMPANY HAVE ENTERED A MULTI-YEAR PARTNERSHIP TO IDENTIFY AND REDUCE DISPARITIES IN CELIAC DISEASE DIAGNOSIS AND MANAGEMENT, AIMING TO RAISE AWARENESS AND HELP MINORITY PATIENTS PARTICIPATE IN CLINICAL TRIALS.THE PARTNERSHIP FOCUSES ON IMPROVING ASPECTS OF DIVERSITY, EQUITY, AND INCLUSION IN CELIAC DISEASE. THIS INCLUDES A DATA ANALYSIS TO IDENTIFY ACCESS BARRIERS TO DIAGNOSIS AND TREATMENT, SUBOPTIMAL CELIAC DISEASE CLINICAL MANAGEMENT, AND UNDERREPRESENTATION OF MINORITY GROUPS IN CLINICAL TRIALS. IN ADDITION, THE PARTNERSHIP AIMS TO EDUCATE AND INCREASE SOCIETAL AWARENESS OF CELIAC DISEASE. BEYOND CELIAC AND THE NATIONAL MINORITY QUALITY FORUM (NMQF) HAVE PARTNERED TO TARGET INEQUITIES IN CELIAC DISEASE DIAGNOSIS, TREATMENT THIS UNIQUE PARTNERSHIP FOCUSES ON THE DISPARITY IN DIAGNOSIS OF CELIAC DISEASE AND IS BUILDING A NEW EQUITABLE PATH FORWARD BY INVESTIGATING THE EXTENT OF UNDIAGNOSED CELIAC DISEASE, PARTICULARLY AMONG NON-CAUCASIANS. MEDICARE AND MEDICAID DATA IS BEING USED TO MAP DIAGNOSED CELIAC DISEASE ACROSS THE UNITED STATES AND TO IDENTIFY POTENTIALLY MISSED AND MISDIAGNOSIS OF THE DISEASE, PARTICULARLY AMONG UNDERSERVED POPULATIONS.
Expenses $1,581,948 · Revenue $586,491
-
GO BEYOND CELIAC: WE CAN, WE WILL GO BEYOND CELIAC, A MAJOR BEYOND CELIAC PROGRAM, IS AN ONLINE CELIAC DISEASE PATIENT REGISTRY AND APP THAT COLLECTS DATA TO ACCELERATE RESEARCH FOR CELIAC DISEASE. THIS IS A PLACE WHERE PATIENTS CAN ACTIVELY PARTICIPATE IN RESEARCH BY SHARING THEIR STORIES AND EXPERIENCES TO HELP IMPROVE DIAGNOSIS AND FURTHER RESEARCH TOWARD TREATMENTS AND A CURE FOR THIS SERIOUS AUTOIMMUNE DISEASE. THIS HELPS RESEARCHERS AND HEALTHCARE PROFESSIONALS TO HAVE A BETTER UNDERSTANDING OF HOW CELIAC DISEASE DEVELOPS. PARTICIPANTS ALSO CAN LEARN ABOUT HOW THEY CAN JOIN RESEARCH STUDIES AND STAY UP TO DATE ON THE LATEST IN CELIAC DISEASE SCIENCE. GO BEYOND CELIAC COLLECTS SELF-REPORTED DATA TO IMPROVE UNDERSTANDING OF CELIAC DISEASE. AS A MEMBER OF THE GO BEYOND CELIAC COMMUNITY, PARTICIPANTS WILL BE ABLE TO ADD THEIR EXPERIENCES TO THE LARGER CELIAC DISEASE PICTURE AND SEE HOW IT COMPARES TO OTHERS. PARTICIPANTS CAN TRACK THEIR HEALTH AND STORE THEIR CELIAC DISEASE-RELATED DATA AND HISTORY IN ONE SAFE PLACE. GO BEYOND CELIAC COLLECTS AND ANALYZES COMPREHENSIVE DATA ON THE BURDEN OF CELIAC DISEASE AND GLUTEN SENSITIVITY. WITH THIS INFORMATION, BEYOND CELIAC CAN INCREASE AWARENESS AND MAKE A COMPELLING CASE FOR LARGER INVESTMENTS FROM GOVERNMENT AGENCIES, PHARMACEUTICAL COMPANIES, BIOTECH AND MORE TO ADVANCE RESEARCH. THROUGH GO BEYOND CELIAC, PARTICIPANTS CAN GET INFORMATION ON THE LATEST IN CLINICAL TRIALS FOR CELIAC DISEASE, INCLUDING WHICH TRIALS ARE CURRENTLY RECRUITING AND HOW PATIENTS CAN GET INVOLVED. CURRENTLY, OVER 8,880 PARTICIPANTS HAVE JOINED GO BEYOND CELIAC TO SHARE THEIR SELF-REPORTED DATA TO IMPROVE UNDERSTANDING OF CELIAC DISEASE. THIS WILL HELP INCREASE DIAGNOSIS AND FURTHER RESEARCH TOWARD NEW TREATMENTS AND A CURE.
Expenses $51,736
-
BEYOND CELIAC RESEARCH AND COMMUNITY SUMMITS BEYOND CELIAC HAS HOSTED RESEARCH AND COMMUNITY SUMMITS BECAUSE SO MANY NEEDS REMAIN UNMET FOR THE CELIAC DISEASE COMMUNITY. BEYOND CELIAC HAS PRODUCED BEYOND CELIAC RESEARCH SUMMITS SINCE 2018, INCLUDING A SUMMIT IN 2022 ENTITLED "THE EVOLVING LANDSCAPE OF CELIAC DISEASE". THIS SUMMIT BROUGHT TOGETHER STAKEHOLDERS CRUCIAL TO ACCOMPLISHING THE GOAL OF DEVELOPING NEW CELIAC DISEASE TREATMENTS. THE 2022 BEYOND CELIAC RESEARCH SUMMIT WAS A CRITICAL NEXT STEP IN WORKING TOGETHER TO DELIVER TREATMENT OPTIONS TO EVERYONE WHO WANTS AND NEEDS THEM. THESE RESEARCH AND COMMUNITY SUMMITS BRING TOGETHER CLINICIAN SCIENTISTS,PATIENTS,ENTREPRENEURIAL DRUG DEVELOPERS, PATIENT ADVOCACY LEADERS, PRIVATE AND PUBLIC HEALTH CARE INSURANCE AND FOOD AND DRUG ADMINISTRATION REPRESENTATIVES. EACH SUMMIT HAS SEVERAL PANEL DISCUSSIONS SUCH AS OUTLINING THE CHALLENGES THAT THE CELIAC COMMUNITY FACES IN MANAGING CELIAC DISEASE, EXPERIENCES THAT COMMUNITY MEMBERS HAVE HAD IN PARTICIPATING IN CLINICAL TRIALS, DRUG DEVELOPMENT, CHALLENGES TO DEVELOPING NON-DIETARY THERAPIES FOR CELIAC DISEASE AND BARRIERS TO RESEARCH.BEYOND CELIAC HELD A COMMUNITY SUMMIT IN 2023 HOSTING OVER 200 PARTICIPANTS. COMMUNITY SUMMIT PARTICIPANTS HAVE THE OPPORTUNITY TO SHARE THEIR EXPERIENCES WITH CELIAC DISEASE, "TOGETHER FOR A CURE."
-
RESEARCH GRANTS HAVE BEEN ISSUED TO FURTHER THE RESEARCH AND STUDY OF CELIAC DISEASE.
Expenses $702,747 · Grants $702,747
As filed on the 2022 return. The filer continues this part on Schedule O, which is not shown here.
Listed in Part VII
-
Alice BastALICE BAST
CEO
- Total calculated
- $314,381
- From this org
- $307,933
- From related orgs
- $0
- Other
- $6,448
- Hours/week
- 60
Schedule J breakdown matched by us
- Base
- $262,933
- Bonus
- $45,000
- Other
- not reported
- Deferred
- not reported
- Nontaxable benefits
- not reported + $6,448 related
- Filer's total
- $307,933 + $6,448 related
-
C Kane BrenanC KANE BRENAN
VICE CHAIR
- Total calculated
- $0
- Hours/week
- 3
-
Alan Ehrlich MDALAN EHRLICH MD
CHAIR
- Total calculated
- $0
- Hours/week
- 4
-
Lawrence P Flynn CPALAWRENCE P FLYNN CPA
TREASURER
- Total calculated
- $0
- Hours/week
- 4
-
Bennett MuskinBENNETT MUSKIN
SECRETARY
- Total calculated
- $0
- Hours/week
- 3
-
Gerald Bertiger MDGERALD BERTIGER MD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 3
-
Barb Weir PowersBARB WEIR POWERS
DIRECTOR
- Total calculated
- $0
- Hours/week
- 3
-
Lisa AgdernLISA AGDERN
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Carole Haas GravagnoCAROLE HAAS GRAVAGNO
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Edward LewinEDWARD LEWIN
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Alison ReemerALISON REEMER
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Jennifer Platzkere SnyderesqJENNIFER PLATZKERE SNYDERESQ
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Brittany BakerBRITTANY BAKER
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Jennifer BrownsteinJENNIFER BROWNSTEIN
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Todd HammerTODD HAMMER
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Gregg MelinsonGREGG MELINSON
DIRECTOR
- Total calculated
- $0
- Hours/week
- 3
-
Sarena SniderSARENA SNIDER
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Ritu Verma MDRITU VERMA MD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Salvatore AlesciSALVATORE ALESCI
CSSO
- Total calculated
- $141,932
- From this org
- $141,404
- From related orgs
- $0
- Other
- $528
- Hours/week
- 40
-
Mary Kate CarofanoMARY KATE CAROFANO
CAO
- Total calculated
- $167,639
- From this org
- $162,249
- From related orgs
- $0
- Other
- $5,390
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $162,249
- Bonus
- not reported
- Other
- not reported
- Deferred
- not reported
- Nontaxable benefits
- not reported + $5,390 related
- Filer's total
- $162,249 + $5,390 related
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.
Schedule J
Answered yes
None.
Answered no
- 4a · Severance or change-of-control payment
- 4b · Supplemental nonqualified retirement plan
- 4c · Equity-based compensation arrangement
- 5a · Pay contingent on this organization's revenues
- 5b · Pay contingent on a related organization's revenues
- 6a · Pay contingent on this organization's net earnings
- 6b · Pay contingent on a related organization's net earnings
- 7 · Other non-fixed payments
- 8 · Paid under the initial-contract exception
Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.
Grants on this return
-
$100,000
RESEARCH
Fundraising and gaming
From Schedule G of this return, as filed.
- Had an agreement with a professional fundraiser (line 2a)
- Not answered
Fundraising events (Part II)
Part II has at most four columns: the two largest events, the rest together, and the total.
| Line | Event 1 GALA | Event 2 5K | Other events 1 events | Total |
|---|---|---|---|---|
| Gross receipts (line 1) | $207,155 | $109,140 | $48,678 | $364,973 |
| Less contributions (line 2) | — | — | — | — |
| Gross income (line 3) | $207,155 | $109,140 | $48,678 | $364,973 |
| Cash prizes (line 4) | — | — | — | — |
| Noncash prizes (line 5) | — | — | — | — |
| Rent and facility costs (line 6) | — | — | — | — |
| Food and beverages (line 7) | — | — | — | — |
| Entertainment (line 8) | — | — | — | — |
| Other direct expenses (line 9) | $44,154 | $23,217 | $89,970 | $157,341 |
- Direct expenses (line 10)
- $157,341
- Net income (line 11)
- $207,632
Activities outside the United States
From Schedule F of this return, as filed.
At most 25 lines of each part are listed here. Schedule F names no grantee, so each line is a region and its money.
Grants to organizations, by region (Part II)
The purpose of each grant is not shown.
| Region | Cash grants | Manner of disbursement | Noncash assistance | Noncash description | Valuation |
|---|---|---|---|---|---|
| ISRAEL | $175,000 | CHECK | — | — | — |
| FINLAND | $100,000 | CHECK | — | — | — |
| UNITED KINGDOM | $174,747 | CHECK | — | — | — |
| PORTUGAL | $100,000 | CHECK | — | — | — |
| UNITED KINGDOM | $53,000 | CHECK | — | — | — |
- Grantees recognized as charities or with a 501(c)(3) equivalency letter (Part II line 2)
- 5
- Other grantees (Part II line 3)
- —
- Transferred property to a foreign corporation during the year (line 1)
- No
- Had an interest in a foreign trust (line 2)
- No
- Owned an interest in a foreign corporation (line 3)
- No
- Was a shareholder of a passive foreign investment company or qualified electing fund (line 4)
- No
- Owned an interest in a foreign partnership (line 5)
- No
- Had operations in or related to a boycotting country (line 6)
- No
Provenance
- Return type
- form_990
- Tax year
- 2022
- Filed
- 22 February 2024
- IRS schema version
- 2022v5.0
- Source object
- 202420539349300727
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.